Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
1 minute read
Sep. 17, 2021
Remibrutinib: An oral BTK-selective covalent kinase inhibitor
remibrutinib
BTK-selective covalent kinase inhibitor Ph. I completed in HV, in Ph. II SBDD from reversible BTK inhibitor and opt. J. Med. Chem., Mar. 4, 2020 Novartis, Basel, CH